| Drugs by Condition |  |
Prevention of Osteoporosis Medications
Drugs (by generic name) associated with Prevention of Osteoporosis
The following drugs and medications are in some way related to, or used in the treatment of Prevention of Osteoporosis. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Drug Name  ( View by: Brand | Generic )
|
Reviews | Ratings |
||
|---|---|---|---|---|
raloxifene systemic (Pro, More...) class: hormones/antineoplastics, miscellaneous hormones | 0 review(s) |  | 9.0 | |
| zoledronic acid systemic (Pro, More...)class: bisphosphonates | 1 review(s) | | 8.0 | |
| ibandronate systemic (Pro, More...)class: bisphosphonates | 1 review(s) | | 7.0 | |
| alendronate systemic (Pro, More...)class: bisphosphonates | 1 review(s) | | 5.3 | |
| risedronate systemic (Pro, More...)class: bisphosphonates | 0 review(s) | Not rated - Be the first | ||
| estradiol/norgestimate systemic (More...)class: hormone replacement therapy, sex hormone combinations | 0 review(s) | Not rated - Be the first | ||
| ethinyl estradiol/norethindrone systemic (Pro, More...)class: contraceptives, hormone replacement therapy, sex hormone combinations | 0 review(s) | Not rated - Be the first | ||
| estradiol/levonorgestrel systemic (Pro, More...)class: hormone replacement therapy, sex hormone combinations | 0 review(s) | Not rated - Be the first | ||
Prevention of Osteoporosis Medications in the Pipeline
- May 27, 2008 - Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
- December 26, 2007 - Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis
- December 17, 2007 - Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
- April 24, 2007 - Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis
- June 26, 2006 - Wyeth Submits Two NDAs for Women’s Health Therapies
- October 21, 2009 - Amgen Provides Update on Status of Prolia (denosumab) Biologics License Application (BLA) Submitted to the U.S. Food and Drug Administration (FDA)
- August 14, 2009 - Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
- February 18, 2009 - FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab
- December 22, 2008 - Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation for Either Prostate or Breast Cancer
Latest Prevention of Osteoporosis Blog Post
Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density
INDIANAPOLIS, April 8, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Phase III data, published online this week in the Journal of Clinical Endocrinology & Metabolism, showed that arzoxifene, an investigational selective estrogen receptor modulator...
View all Prevention of Osteoporosis blog posts.
Prevention of Osteoporosis Support Group Questions
Go to the Prevention of Osteoporosis support group or view all Prevention of Osteoporosis questions.
